SMARCAL1 and cancer: By identifying SMARCAL1 as a dual regulator that simultaneously suppresses innate immune signaling and promotes immune checkpoint expression, this research suggests that targeting SMARCAL1 could provide a multifaceted approach to cancer treatment.